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The range of doses achieved for D2cc Rectum was 52.46 Gy to 
138.27 Gy. 85% of cases achieved D10 Urethra of less than 
217.5Gy, whilst 100% achieved doses of less than 240 Gy. The 
range of doses for D30 Urethra was 172.08 Gy to 222.35 Gy. 
64% of cases received doses greater than 188.5Gy but only 
7.4% of cases received doses greater than 208 Gy. Only 1 
patient required re-catheterisation post procedure. 
Conclusions: The median dosimetric parameters ascribed to 
a 145Gy prescription dose were achieved for all GEC-ESTRO 
described organs at risk, except for the secondary OAR 
parameter of D30 Urethra, using a prescription dose of 160Gy. 
The low rectal doses are noteworthy as is the low rate of re-
catheterisation. This indicates that 160Gy can be safely 
delivered which may in turn improve outcomes. 
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Purpose/Objective: To evaluate two different types of 
stranded seeds in permanent prostate brachytherapy. In the 
first group we used strands with a fixed sequence of seeds 
and spacers, in the second group we could implant strands 
with a variable sequence of seeds and spacers. 
Materials and Methods: From 2007 to 2014 we treated a 
total of 110 low-risk prostate cancer patients with either the 
fixed (IsoCord®, Eckert & Ziegler Bebig, n=74) or the variable 
spacing (Quicklink®, C.R. Bard, n=36) system. Median patient 
age was 65.5 years. All patients were treated by the same 
team of radiation oncologist, urologist and physicist. 
Treatment planning parameters were compared at seed 
implantation and at post-planning 4 weeks later. Toxicities 
and quality of life were evaluated according to CTCAE v4 and 
the EORTC QLQ-C30 and PR-25 questionnaires. To evaluate 
obstructive problems we used the IPSS scoring system. 
Results: Mean prostate volumes were 30.4+11ccm and 
36.9+11ccm (p=0,004). A mean of 52 vs 59 Seeds per patient 
were implanted (p<0,001). At implantation values for D90 
(191.9 vs. 179.9Gy; p<0,001), V100 (99.1 vs. 97.6%; p<0,001), 
V150 (78.5 vs. 70.5%; p<0,001) and V200 (45.1 vs. 37.9%; 
p<0,001) were significantly different. Also D1 for urethra was 
less for the group with variable spacing (225.9 vs. 206.8Gy; 
p<0,001). We observed significant differences at post-
planning in the following DVH parameters: D90 (165.7 vs. 
171.9Gy; p=0,008) and V100 (94.6 vs. 96.0; p<0.001). The 
reduction in D90 values were significantly greater for the 
fixed system (13.7% vs. 4.6%; p<0.001). Homogeneity index 
was significantly different at implantation (20.8 vs. 27.2%) 
but not at post planning (24.8 vs. 25.0%). There were no 
significant changes in rectal V100 and prostate V150 and 
V200. Evaluation of toxicities, IPSS scores and comparison of 
quality of life parameters is still ongoing and will be 
presented at the conference. 
Conclusions: Using the stranded seed system with variable 
spacing we could achieve a reduced dose to the urethra at 
implantation and observed more stable values for prostate 
D90 at post-planning dosimetry.  
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Purpose/Objective: Development of new technologies and 
the applicator MRI studies for the intracavitary radiation 
therapy for cancer of the anal canal, with the aim 
Enhancements treatment results and brachytherapy planning 
and optimization The prognostic relevance of tumor human 
papilloma virus (HPV) status in patients with anal squamous 
cell carcinoma. 
Materials and Methods: in 2012-2014 40 invasive anal 
channel cancer T1-4 N0-1 M0 patients were treated with 
combined chemoradiotherapy. First the patients received 
chemoradiotherapy using cisplatin and capecitabin. EBT was 
performed for minor pelvis and local lymph nodes using a 3D 
technique, since 2010 using IMRT and RapidArc. Total dose 
was 45 Gr. HPV status was revealed using an anal channel 
smear and PCR. At the second phase of radiotherapy - 
brachytherapy applicator used by us made, 25mm diameter, 
with 6 peripheral channels and one central, for the 
MicroSelectron was performed: All training conducted 
dosimetry using MRI scans. Optimal single dose per fraction is 
calculated by a special formula.  
The irradiation was performed three a week, 3 Gy per 
fraction. 5-6 fractions were performed. Total radiation 
dose=18-21Gy. 
Comparison and optimization treatment plans was performed 
with the following parameters: Coverage index, External 
volume index, Relative Dose Homogeneity index, Overdose 
volume index. 
Results: 36 patients out of 40 achieved complete regression 
of the tumor. Annual relapse-free survival rate was 98 
percent of 40 patients, 36 had positive HPV status. Full 
regress of the primary tumor was obtained in 36 (100%) 
patients. Of HPV negative status patients, full response was 
obtained only in 1 patient. 
Conclusions: Applying the new applicator may achieve 
optimal dose distribution and to achieve a greater 
percentage of complete regression. In anal channel patients 
receiving combined chemoradiotherapy, an HPV positive 
status is a favorable prognostic factor of a tumor´s 
radiosensitivity. 
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Purpose/Objective: Standard management of low rectal 
cancer is radical surgery often combined with pre-operative 
External Beam Radiotherapy (EBRT) ± chemotherapy. Despite 
advances in surgical techniques permanent stoma formation 
can be unavoidable. Contact radiotherapy (CBT) offers an 
alternative to surgery. Potentially operable patients must 
understand close follow up is required as the risk of local 
recurrence is greater, though with salvage surgery overall 
survival appears not to be affected. St Luke’s Cancer Centre 
offers this treatment via a 50kV orthovoltage machine 
(Ariane, Derby, UK). This service commenced in April 2014. 
We report response assessment using MRI in potentially 
operable patients with a minimum of 3 months follow up. 
Materials and Methods: 15 patients have been treated to 
date. Median age is 62 years (51 to 87 years), 10 male and 5 
female patients were treated. Clinical staging ranged from 
T2N0 to T3N1. All cancers were histologically confirmed 
adenocarcinomas. Treatment was planned via the 
multidisciplinary team. One patient was excluded from this 
analysis as who developed progressive disease and was 
offered immediate surgery.  
All patients received EBRT 45Gy/25 fractions with a CBT 
boost of 90Gy in 3 fractions. Median duration of CBT boost 26 
days (24-30 days). 
Results: 3 Patients with tumours <3cm at presentation had 
CBT prior to EBRT. 12 patients had CBT boost post EBRT.  
Median follow up is 4 months (3-7 months). 14 Patients have 
had 3 month MRI scans, all of which show radiological 
complete response with no tumour seen (TRG1). 
Complications: Acute toxicity is recorded at subsequent clinic 
visits. This treatment is well tolerated, and only Grade 1 
diarrhoea and rectal bleeding have been reported. 
Conclusions: With appropriate counselling patients can make 
an informed decision to have stoma-sparing treatment 
potentially at the expense of an increased local failure rate. 
Early results show good response to treatment with 
acceptable toxicity. Complete resolution of tumour was seen 
in all cases where treatment was completed as planned. 
These patients will remain under follow up for tumour 
control and late toxicity. 
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Purpose/Objective: to present the treatment regimen and 
contention method, used to treat surgically mistreated or 
recurrent facial skin cancer and skin metastatic breast 
lesions, with HDR Plesiotherapy (PT) 
Materials and Methods: a total of 170 treatments were 
performed in 15 patients: 9 with basal or squamouscell 
carcinoma (1 was treated twice); 6 with progressive 
extension of thoracic skin breast metastasis (1 was treated 
twice). These last patients were treated in and out of the 
previously irradiated zone (2 to 7 years). The planning 
method was identical for all the patients. One or several 
zones (1-6) were carefully delineated with a radiopaque 
marker, then covered with a moulded thermoplastic facial or 
thoracic mask for strict immobilization and reproductibility; 
the first bolus plaque was applied on the mask and 6 Fr 
plastic tubes were placed 10 mm apart above the treatment 
zone, and immobilized by 2 more plaques. The dosimetry 
done with CT images allows for the selection of the depth 
from 3-6 mm of the prescribed dose. For all patients, the 
total delivered dose was 40 Gy in 5 weeks, 10 fractions, 
twice a week. Every patient had a photo file with pre-
treatment, simulation, reactions during HDR PT, and follow 
up pictures, in order to afford an eventual re-treatment. 
Results: all 15 patients, including the 2 re-treated for vicinity 
cancer progression, are macroscopically disease free after 
HDR PT with follow up times of 4 to 26 months. Two patients 
with wide thoracic multi irradiated zones had a 1 week 
treatment interruption due to radioepithelitis. Complete 
healing occured 2 weeks after the end of PT, but 1 thoracic 
patient needed 7 weeks. The final cosmetic results were also 
dependent on the previous treatment (surgery or RT): 8 
excellent, 1 good for the facial group; 3 good, 2 medium, 1 
bad for the thoracic group. 
Conclusions: HDR PT is a good treatment for primary skin 
cancer and skin breast metastatsis with progressive 
extension. The three dimensional dosimetry and contention 
mask ensure the reproductibility of the delineated zone at 
the chosen depth. This precision allows for re- treatments in 
close vicinity even with an irregular shape. With this regimen 
we achieved a good oncological control and cosmetic results 
with a low complication rate. New superficial locations are 
now in experience. 
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Purpose/Objective: To evaluate clinical value of HDR 
brachytherapy in patients with non-operable recurrent 
malignant soft tissue sarcomas (MSTS) and role of 99mTc-MIBI 
SPECT-CT imaging in therapy planning and monitoring of its 
efficacy 
Materials and Methods: The study group consisted of 9 
patients with RSTS that were inoperable (2 patients with 
pelvic tumours) or considered as candidates for amputation 
(7 patients with MSTS of extremities). Tumor volume varied 
